At the time of writing, Novavax, Inc. [NVAX] stock is trading at $12.38, up 8.60%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NVAX shares have gain 3.25% over the last week, with a monthly amount drifted -1.51%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Novavax, Inc. [NASDAQ: NVAX] stock has seen the most recent analyst activity on July 30, 2024, when JP Morgan downgraded its rating to a Underweight but kept the price target unchanged to $8 for it. Previously, JP Morgan upgraded its rating to Neutral on May 10, 2024. On May 10, 2024, upgrade upgraded it’s rating to Neutral and revised its price target to $12 on the stock. B. Riley Securities upgraded its rating to a Buy but stick to its price target of $15 on August 09, 2023. TD Cowen downgraded its rating to a Market Perform and reduced its price target to $10 on April 20, 2023. B. Riley Securities downgraded its rating to Neutral for this stock on March 01, 2023, and downed its price target to $10. In a note dated January 09, 2023, B. Riley Securities reiterated an Buy rating on this stock and revised its target price from $74 to $37.
For the past year, the stock price of Novavax, Inc. fluctuated between $3.53 and $23.86. Currently, Wall Street analysts expect the stock to reach $74.67 within the next 12 months. Novavax, Inc. [NASDAQ: NVAX] shares were valued at $12.38 at the most recent close of the market. An investor can expect a potential return of 503.15% based on the average NVAX price forecast.
Analyzing the NVAX fundamentals
According to Novavax, Inc. [NASDAQ:NVAX], the company’s sales were 987.67M for trailing twelve months, which represents an -2.11% plunge. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at -0.35%, Pretax Profit Margin comes in at -0.35%, and Net Profit Margin reading is -0.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is 0.44 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.51 points at the first support level, and at 10.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.87, and for the 2nd resistance point, it is at 13.35.
Ratios To Look Out For
It is important to note that Novavax, Inc. [NASDAQ:NVAX] has a current ratio of 1.04. As well, the Quick Ratio is 1.03, while the Cash Ratio is 0.6. Considering the valuation of this stock, the price to sales ratio is 2.01.
Transactions by insiders
Recent insider trading involved YOUNG JAMES F, Director, that happened on Jun 21 ’24 when 7500.0 shares were sold. Director, YOUNG JAMES F completed a deal on Jun 18 ’24 to sell 7500.0 shares. Meanwhile, President, R&D Dubovsky Filip sold 13904.0 shares on Jun 17 ’24.
